Today’s Stock On Watch: Bluebird Bio Incorporated (NASDAQ:BLUE) Reports Increase in Sellers; Strong Momentum for Short Players

November 28, 2016 - By Hazel Jackson   ·   0 Comments

Today's Stock On Watch: Bluebird Bio Incorporated (NASDAQ:BLUE) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of Bluebird Bio Incorporated (NASDAQ:BLUE) registered an increase of 6.11% in short interest. BLUE’s total short interest was 9.19 million shares in November as published by FINRA. Its up 6.11% from 8.66 million shares, reported previously. With 1.03 million shares average volume, it will take short sellers 9 days to cover their BLUE’s short positions. The short interest to Bluebird Bio Incorporated’s float is 26.56%. The stock increased 2.32% or $1.45 on November 25, hitting $63.95. bluebird bio Inc (NASDAQ:BLUE) has risen 35.72% since April 25, 2016 and is uptrending. It has outperformed by 29.70% the S&P500.

bluebird bio, Inc. is a biotechnology company. The company has a market cap of $2.44 billion. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. It currently has negative earnings. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Insitutional Activity: The institutional sentiment increased to 1.48 in Q2 2016. Its up 0.48, from 1 in 2016Q1. The ratio improved, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Tiaa Cref Mngmt Ltd Liability reported 151,224 shares or 0.01% of all its holdings. Columbus Circle Investors holds 0.09% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 201,150 shares. Wellington Grp Llp owns 2.08 million shares or 0.02% of their US portfolio. Williams Jones Llc holds 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 5,850 shares. Teachers Advsr, a New York-based fund reported 75,356 shares. Croft holds 6,000 shares or 0.06% of its portfolio. Rhumbline Advisers has invested 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Employees Retirement Association Of Colorado accumulated 7,118 shares or 0% of the stock. Rock Springs Capital Management Lp last reported 20,000 shares in the company. Great Point Ptnrs Ltd Liability has invested 6.2% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Sandy Spring National Bank & Trust has invested 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Highlander Mgmt Ltd Liability Corp reported 1,500 shares or 0.06% of all its holdings. Allianz Asset Management Ag accumulated 0% or 15,697 shares. First Light Asset Mgmt Ltd Liability Company has invested 1.34% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Moreover, Sphera Funds Management Ltd has 0.45% invested in bluebird bio Inc (NASDAQ:BLUE) for 40,000 shares.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Out of 14 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 71% are positive. $244 is the highest target while $14 is the lowest. The $108.27 average target is 69.30% above today’s ($63.95) stock price. bluebird bio has been the topic of 29 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, November 18 by Goldman Sachs. On Monday, August 24 the stock rating was maintained by JP Morgan with “Overweight”. The company was initiated on Friday, June 3 by Cantor Fitzgerald. TH Capital initiated the stock with “Buy” rating in Thursday, December 3 report. The stock has “Buy” rating given by Goldman Sachs on Thursday, September 15. The firm has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. The stock of bluebird bio Inc (NASDAQ:BLUE) has “Buy” rating given on Tuesday, January 5 by Maxim Group. The rating was upgraded by Morgan Stanley on Monday, October 5 to “Overweight”. On Thursday, December 3 the stock rating was initiated by Roth Capital with “Buy”. The firm has “Buy” rating given on Thursday, September 22 by Roth Capital.

BLUE Company Profile

bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

More recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio Inc. Got Knocked Down Today” on November 03, 2016. Also Fool.com published the news titled: “Why bluebird bio Inc. Stock Jumped Today” on November 14, 2016. Fool.com‘s news article titled: “Why bluebird bio, Inc. Stock Got Crushed in October” with publication date: November 10, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>